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ABSTRACT
OBJECTIVE
To assess the effectiveness of the NHS Cancer Plan 
(2000) and subsequent national cancer policy 
initiatives in improving cancer survival and reducing 
socioeconomic inequalities in survival in England.
DESIGN
Population based cohort study.
SETTING
England.
POPULATION
More than 3.5 million registered patients aged  
15-99 with a diagnosis of one of the 24 most 
common primary, malignant, invasive neoplasms 
between 1996 and 2013.
MAIN OUTCOME MEASURES
Age standardised net survival estimates by cancer, 
sex, year, and deprivation group. These estimates 
were modelled using regression model with splines to 
explore changes in the cancer survival trends and in 
the socioeconomic inequalities in survival.
RESULTS
One year net survival improved steadily from 1996 
for 26 of 41 sex-cancer combinations studied, and 
only from 2001 or 2006 for four cancers. Trends 
in survival accelerated after 2006 for five cancers. 
The deprivation gap observed for all 41 sex-cancer 
combinations among patients with a diagnosis in 
1996 persisted until 2013. However, the gap slightly 
decreased for six cancers among men for which one 
year survival was more than 65% in 1996, and for 
cervical and uterine cancers, for which survival was 
more than 75% in 1996. The deprivation gap widened 
notably for brain tumours in men and for lung cancer 
in women.
CONCLUSIONS
Little evidence was found of a direct impact of 
national cancer strategies on one year survival, 
and no evidence for a reduction in socioeconomic 
inequalities in cancer survival. These findings 
emphasise that socioeconomic inequalities in survival 
remain a major public health problem for a healthcare 
system founded on equity.
Introduction
Differences in cancer survival between less and more 
deprived patients have been well documented for most 
types of cancer and in different geographical settings.1-7 
There is evidence for some explanations related to 
patient, tumour, and healthcare characteristics, but 
these can only explain part of the differences depending 
on the cancer type and healthcare system.8 9 Cancer 
survival in England has been improving steadily 
since the 1970s,10 but socioeconomic inequalities in 
survival persist for most cancers,11 despite concerted 
efforts and investment in the National Health Service.
After the Calman-Hine report in 1995,12 the first fully 
detailed strategy to tackle cancer in England was the 
NHS Cancer Plan,13 introduced in 2000. It set out the 
government’s plans for investment and reform, aiming 
at improving prevention, delivery of care (including 
implementation of multidisciplinary teams), and 
research. It led to an inflation adjusted increase of 35% 
in annual expenditure on cancer services between 
2001 and 2004. Among the main aims were improving 
cancer survival to levels comparable with the rest of 
Europe and reducing socioeconomic inequalities. 
In 2007, the Cancer Reform Strategy14 focused on 
consolidation of progress made since publication of the 
NHS Cancer Plan and set out plans for cancer services 
over the ensuing five years. Again, tackling inequalities 
and promoting equality in access to cancer services in 
England were central to the strategy, which also led to 
the foundation of the National Cancer Equality Initiative 
in 2008, a multidisciplinary initiative dedicated to 
this purpose.15 In 2008, the National Awareness and 
Early Diagnosis Initiative (NAEDI) was launched, with 
the purpose of stimulating action to diagnose cancer 
earlier and improve cancer outcomes. Some of the 
key target areas were tackling negative attitudes to 
cancer and the barriers to seeing a doctor, supporting 
primary care, and optimising access to diagnostic 
tests and referral pathways. These initiatives occurred 
concomitantly with major reorganisation of the NHS 
and funding pressure on NHS spending (reduction of 
the health spend as a proportion of the gross domestic 
product) after publication of a white paper in 2010.16
We investigated the effectiveness of the NHS Cancer 
Plan and subsequent strategies in improving one year 
survival and reducing socioeconomic inequalities in 
cancer survival, up to 14 years after the introduction 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Cancer survival in England has been improving steadily for all deprivation 
groups since the 1970s, but still lags behind that seen in comparable countries 
in Europe
A “deprivation gap” in survival persists between the least and the most deprived 
in England
WhAT ThIS STudy AddS
Even though increasing cancer survival and reducing inequalities in survival have 
been among the main targets of national cancer policy initiatives implemented 
since 2000, this study found little evidence of a direct impact of these strategies 
on one year survival, and no evidence for a reduction in socioeconomic 
inequalities in survival
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of the plan, in the context of major changes in the 
NHS since 2010. We focused on one year survival 
because most inequalities in cancer survival in 
England arise shortly after diagnosis.17 We examined 
trends in cancer survival and in the deprivation gap 
in survival for patients receiving a diagnosis in three 
predefined calendar periods: 1996-2000 (before the 
cancer plan), 2001-05 (initialisation period), and 
2006-13 (implementation period), with follow-up to 
2014. This allowed comparison of trends before and 
after introduction of the NHS Cancer Plan, including 
an initialisation period to reflect the latency before 
such an extensive and wide ranging strategy might 
take effect. We also analysed the changes in survival 
patterns without fixing the calendar periods a priori, 
to examine survival trends after the successive cancer 
policy initiatives but without imposing assumptions 
on the calendar periods during which those changes 
might occur.
Methods
Data
We extracted data from the population based 
National Cancer Registry database held by the Office 
for National Statistics (ONS). The primary source of 
cancer registration records is a range of healthcare 
providers, such as hospitals, pathology laboratories, 
and other services that provide all the information on 
the cancer diagnoses in a given year. This information 
is collected and maintained by the National Cancer 
Registration and Analysis Service in Public Health 
England, which actively updates the database for 
up to nine months after the registration year. The 
vital status of registered patients with cancer (alive, 
emigrated, dead, not traced) is updated by ONS 
and the HSCIC (Health and Social Care Information 
Centre, now known as NHS Digital). The estimated 
completeness of this dynamic database is 98% at 
the registration calendar year, but it can reach 100% 
within five years.18 19
We included all young people and adults (age 15-99 
years) with a diagnosis of one of the 24 most common 
primary, malignant (ICD-O (international classification 
of diseases for oncology) behaviour code 3), invasive 
neoplasms between 1996 and 2013, with potential 
follow-up until the end of 2014. These represent about 
91% of all cancers diagnosed in England. Tumour 
site was coded according to ICD-10 (international 
classification of diseases, 10th revision),20 whereas 
morphology and behaviour were coded according 
to the international classification of diseases for 
oncology, second edition (ICD-O-2).21 The data owners 
undertake various cleaning procedures to ensure high 
quality of the data, but we also apply a standard set 
of additional checks for cancer survival analysis, 
aiming to flag or exclude incomplete, ineligible, or 
incoherent tumour records, as well as second or higher 
order tumours arising in the same organ as a previous 
primary cancer.22 Overall, these procedures led to 
exclusion of less than 5% of patients. The analyses 
included over 3.5 million patients.
Deprivation
The index of multiple deprivation (IMD 2004)23 is 
an ecological measure of deprivation, with seven 
distinct domains and a combined measure, assigned 
to individuals living within a given Lower-layer 
Super Output Area (LSOA). LSOAs are administrative 
geographical areas established to improve reporting 
of small area statistics in England and Wales. Patients 
with cancer were assigned to one of 32 482 LSOAs in 
England (mean population 1500) on the basis of their 
postcode of residence at diagnosis. For our study we 
used the income domain score, which measures the 
proportion of the population with low income in a 
given LSOA. The five deprivation categories were based 
on the fifths of the national distribution of scores for 
the 32 482 LSOAs in England and patients with cancer 
were assigned to the deprivation category of their LSOA 
(from 1 indicating “least deprived,” or affluent, to 5 
indicating “most deprived”).
Net survival estimation
We estimated one year net survival for each cancer by 
sex, year of diagnosis (1996 to 2013), and deprivation 
category. Patients with a diagnosis between 1996 and 
2013 had the potential to be followed up for at least 
one year, so we used the classic cohort approach.
Net survival is the probability of survival if cancer 
were the only possible cause of death. It is the only 
survival measure enabling comparisons between 
populations (ie, between periods and socioeconomic 
levels) in which mortality hazard from other causes 
may differ, because this measure does not depend 
on these hazards. Estimation of net survival requires 
the comparison of the overall mortality hazard 
experienced by the patients with cancer to their 
expected mortality hazard—that is, hazard from other 
causes of death. This leads to an estimate of the excess 
mortality hazard (ie, hazard of death due to the cancer 
of interest), which mathematically is the complement 
of net survival.24 Because the cause of death is not 
considered as reliable in population based data, the 
expected mortality hazard of the patients with cancer 
is estimated in the general population that the patients 
come from. We therefore built life tables for the 
England general population by calendar year, sex, age, 
and deprivation.25 26 In the absence of data on recent 
deaths in the general population, we used the 2011 
mortality rates for 2012 and 2013.
We estimated net survival using the consistent non-
parametric estimator defined by Pohar-Perme.27 This 
estimator accounts for the informative censoring due to 
patient factors such as age—that is, when some groups 
of patients are more likely to be censored because of 
death from other causes. The estimator is implemented 
in Stata 1428 within the stns command.29
Age standardisation
Survival estimates for all ages combined were age 
standardised with the International Cancer Survival 
Standard weights.30 Age standardisation required 
to estimate survival in 18 450 unique combinations 
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of cancer (20 in men and 21 in women), sex, year of 
diagnosis (18 years), deprivation (five categories), and 
age groups (five groups). In 562 of these combinations 
it was not possible to estimate survival owing to sparse 
data. In those cases, we combined the data for adjacent 
age groups and assigned the pooled survival estimate 
to both age groups, the corresponding weights for 
these age groups being also combined. If survival 
estimates were missing for more than one age group, 
we report only the unstandardised survival estimate 
(382 combinations). These issues arose mostly for 
mesothelioma, thyroid and testicular cancer, Hodgkin 
lymphoma, and myeloma, which tend to be rare in 
either very young or very old patients.
Trends in survival, deprivation gap, and trends in 
deprivation gap
We used multivariable linear regression to investigate 
the survival patterns for each cancer and by sex. The 
outcome was one year age standardised net survival 
and the predictors were year of diagnosis (representing 
the trend) and deprivation. The model also included an 
interaction between year of diagnosis and deprivation, 
which defined the temporal trend in the deprivation 
gap: the significance level of this term was set at 0.05. 
This allowed us to test the statistical significance of the 
interaction and to decide if there was evidence for a 
change in the deprivation gap.
A continuous linear effect was considered for the 
effect of deprivation. We tested a series of linear 
restricted regression splines with constrained knot 
location for the effect of year and the interaction term. 
Knots were fixed at the calendar years 2001 and 2006, 
to align with the three periods we defined in relation 
to the NHS Cancer Plan. The final number of knots 
was determined with an algorithm embedded in the 
mvrs program in STATA.31 Starting with the model of 
maximum complexity, this closed-test algorithm uses a 
backward elimination to choose the best fitting spline, 
while the overall type I error is kept at a predefined 
level (here 5%).
From the regression models applied to the entire 
dataset for each sex-cancer combination we estimated 
both survival and the deprivation gap in survival for 
each year. Survival is the predicted age standardised 
one year net survival for patients with a diagnosis in 
each calendar year. The deprivation gap is the absolute 
difference between the predicted net survival estimates 
for the most affluent and most deprived groups (fig 1). 
By convention, a negative value for the deprivation 
gap implies that survival was lower in deprived than in 
affluent patients. We derived 95% confidence intervals 
from the linear combination of coefficients acquired 
from the flexible models.
Relaxed assumptions
Our main analysis incorporated the assumption that 
2001 and 2006 were starting points for any change in 
the slope of the trend in survival or in the deprivation 
gap in survival. We then relaxed this assumption by 
including an internal knot for each year in the initial 
model, again allowing the knots to be selected by 
the algorithm embedded in the command.31 The 
deprivation gap was derived from the same final 
models as described previously. We performed similar 
analyses using cubic splines to allow for the possibility 
of non-linear trends.
Patient involvement
This study is part of the Cancer Survival Group’s 
commitment to describe and explain inequalities in 
cancer survival affecting older patients, patients of 
low socioeconomic status, and all patients living in 
England and in the UK, where cancer survival still lags 
behind survival in other comparably wealthy countries.
We repeatedly receive feedback from patients 
with cancer and advocacy bodies at national and 
international meetings to the effect that the cancer 
survival statistics we produce are an invaluable support 
for their efforts to lobby for improved care of patients 
with cancer. We have a longstanding collaboration 
with the National Cancer Research Institute Consumer 
Liaison Group—a group of patients’ representatives 
that is actively involved in our research. We organise 
regular meetings at which we discuss our research, 
exchange ideas, and receive valuable feedback. More 
than 40 members of this group participated in our 
most recent meeting, on 13 February 2017, at which 
our research (including this study) was presented and 
discussed in plenary session and in small groups. 
Two patients are also members of the Advisory Panel 
for the Cancer Survival Programme, of which this 
study is a component part. We recently received 
special recognition from Cancer Research UK for the 
involvement and engagement of patients in the design 
and delivery of our research.
Our international research programme on cancer 
survival is also officially endorsed by many cancer 
patient bodies, including the Association of European 
Cancer Leagues (Brussels, Belgium), the European 
Institute for Women’s Health (Dublin, Ireland), and 
the European Cancer Patient Coalition. These agencies 
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have all used our cancer survival estimates to press 
for improvements in cancer care locally, but also to 
improve cancer policy nationally.
Results
Trends in one year net survival
One year survival improved for 20 of the 21 cancers 
examined in women and 16 of the 20 cancers examined 
in men (table 1).
The largest improvements were observed for cancers 
that were of poor or intermediate prognosis in the 
1990s (<65% for those with a diagnosis in 1996), 
such as cancers of the oesophagus, liver (men), lung 
(women), and kidney, mesothelioma, and myeloma. 
For these cancers, the average annual absolute 
increase in one year age standardised net survival was 
often greater than 1% over the whole study period (fig 
2). Survival for men diagnosed as having cancer of the 
larynx or testis, or Hodgkin lymphoma, was already 
high in the 1990s, and it improved little by 2013.
For 26 of the 41 cancer-sex combinations, survival 
improved steadily from 1996, but with no statistically 
significant acceleration after 2006, ie, after the 
predefined implementation period. This was the 
case for eight of the 20 malignancies in men: six 
cancers of the digestive tract, melanoma, and non-
Hodgkin lymphoma; and for 18 of 21 malignancies 
in women: six cancers of the digestive tract, lung 
cancer, mesothelioma, melanoma, four gynaecological 
cancers, brain cancer, thyroid cancer, non-Hodgkin 
lymphoma, myeloma, and leukaemia.
Changes in the survival trend were observed for 
several cancers. For mesothelioma in men, one year 
survival changed little during 1996-2000 (mean 
annual increase 0.2%), but accelerated to 1.3% 
each year during 2001-13 (table 1). A similar change 
occurred for brain tumours in men at the same time 
point (0.2% to 1.1% each year).
For thyroid cancer in men, one year survival changed 
little during the 10 year period 1996-2005, but then 
increased by 1.1% each year between 2006 and 2013. 
A similar pattern was seen for Hodgkin lymphoma in 
women, which increased by 0.5% a year between 2006 
and 2013.
The one year survival trends seen during 1996-2005 
accelerated from 2006 for lung cancer, myeloma, and 
leukaemia in men, and for kidney cancer in both sexes. 
The average annual increases during 1996-2005 
were less than 1% a year, but increased up to 2% a 
year between 2006 and 2013. For kidney cancer, the 
annual rate of increase in one year survival doubled 
from 2006, increasing from 0.6% to 1.4% a year in 
men, and from 0.8% to 1.5% a year in women.
For prostate cancer, the mean annual increase in one 
year survival was 1.2% during 1996-2000, null during 
2001-05, and 0.6% during 2006-13; by 2013, one 
year survival had reached 92.1%.
When we relaxed the assumption that the trend 
could only change in 2001 or 2006, fitting flexible 
splines that allow the trend to change from year to 
year, the results differed little (data not shown).T
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Deprivation gap in one year net survival and trends
When survival increased, it concerned all deprivation 
groups for most sex-cancer combinations. Survival 
nevertheless remained consistently lower among 
more deprived patients than the less deprived, and 
the deprivation gap in one year net survival remained 
unchanged for 13 cancers in men and 17 cancers in 
women between 1996 and 2013 (fig 3). The survival 
gap narrowed only in six out of 20 cancers among 
men and in two out of 21 cancers among women, and 
widened for three cancers. All these changes were 
linear. The deprivation gaps were more similar between 
men and women in 2013 than in 1996.
In 1996 there was a clear deprivation gradient in one 
year survival, which was lower among more deprived 
than less deprived patients, for all cancers and in both 
sexes (tables 2 and 3). Seventeen years later, in 2013, 
survival was still lower among the more deprived 
groups for all cancers, except Hodgkin lymphoma in 
men. A narrowing in the deprivation gap was observed 
for cancers with survival in 1996 near or higher than 
65% among men and 75% among women.
In 1996, the largest deprivation gap in men was 
observed for rectal cancer (−9.4%) and non-Hodgkin 
lymphoma (−8.2%). The deprivation gap narrowed 
slightly by 1.6% during 1996-2013 for both colon and 
rectal cancer, and by 1.3% for non-Hodgkin lymphoma. 
However, the largest reduction was seen for Hodgkin 
lymphoma (3.7%) and prostate cancer (3.2%). For 
melanoma of the skin, the deprivation gap decreased 
by 3.5% between 1996 and 2013. The deprivation 
gap for these cancers ranged from −6.2% to −4.6% 
in 1996. In 2013, the largest deprivation gap was for 
rectal cancer (−7.8%) and brain cancer (−7.5%).
In women, the largest deprivation gap in 1996, as in 
2013, was for bladder cancer (−8.6%), mesothelioma 
(−8.3%), and oesophageal cancer (−8%). A reduction 
was only seen for cervical cancer (from −7.0% in 1996 
to −3.5% in 2013) and uterine cancer (from −5.8% to 
−2.8%, respectively).
The deprivation gap in survival widened for brain 
tumours in men and lung cancer in women, by 5.1% 
(from −2.4% in 1996 to-7.5% in 2013) and 1.1% (from 
−3.7% in 1996 to −4.8% in 2013), respectively.
The deprivation gap was narrow in 1996 for a few 
malignancies and remained among the narrowest in 
2013: Hodgkin lymphoma (−1.9%) and skin melanoma 
(−1.9%) in women, and thyroid (−2.7%) and testicular 
cancers (−2.8%) in men.
discussion
A steady improvement in one year net survival was 
seen between 1996 and 2013 in England for nearly 
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Fig 2 | Change in one year net survival between 1996 
and 2013 for 20 cancers in men and 21 cancers in 
women, arrayed by ICD-10
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all 41 cancer-sex combinations. In 2013, one year 
net survival was higher than 80% for 17 cancer-
sex combinations, but this encouraging picture is 
moderated by the 14 poor prognosis combinations 
with one year survival still below 50%. Acceleration 
of this overall improvement was rarely observed, 
offering little evidence for a direct impact of the NHS 
Cancer Plan (2000) and later policy initiatives on 
short term cancer survival. Meanwhile, the deprivation 
gap in one year net survival remained unchanged for 
most cancers, with a clear, persistent pattern of lower 
survival among more deprived patients. Reduction of 
socioeconomic inequalities was seen only among some 
cancers for which one year survival was already more 
than 65% in 1996, especially among men, suggesting 
a ceiling effect in that survival has reached a maximum 
among the least deprived patients.
The successive national policy initiatives, including 
the 2000 Cancer Plan for England, aimed to improve 
cancer survival, with the target of bringing survival 
to the level of comparably wealthy countries, and to 
reduce the inequalities in cancer survival. The lack of 
consistent results between men and women, as well 
as the lack of general patterns across cancer types, 
provide little evidence for any strong impact of the 
national cancer policies on short term cancer survival. 
The evidence is even weaker for their impact on the 
socioeconomic inequalities in cancer survival.
Strengths and weaknesses of this study
A major strength of this study is that it is based on 
virtually all cancer cases registered in England, and 
the quality and completeness of the English cancer 
registry data are acknowledged to be high.32 The study 
also updates by seven years our previous evaluations,11 
17 33 with a total of 18 years of incidence data. These 
extra years of data allowed us to estimate the trends 
more accurately.
Since our previous evaluations new, more flexible 
methodologies were introduced. The assumption that 
trends in survival and in deprivation gap should be 
different in three predefined periods11 was now relaxed 
Table 2 | Adjusted one year survival and change in net survival for men with a diagnosis of one of 20 cancers between 1996 and 2013
Malignancy
1996 2001 2006 2013 1996-2013
Survival in 
most affluent 
(95% CI)
Deprivation gap 
(95% CI)
Survival in 
most affluent 
(95% CI)
Deprivation 
gap (95% CI)
Survival in 
most affluent 
(95% CI)
Deprivation 
gap (95% CI)
Survival in 
most affluent 
(95% CI)
Deprivation gap 
(95% CI)
Change in 
deprivation 
gap (%)
Oesophagus 32.4  
(31.4 to 33.3)
−7.3  
(−8.4 to −6.3)
38.6  
(37.9 to 39.3)
−7.3  
(−8.4 to −6.3)
44.8  
(44.0 to 45.7)
−7.3  
(−8.4 to −6.3)
50.6  
(49.5 to 51.7)
−7.3  
(−8.4 to −6.3)
0.0
Stomach 37.8  
(36.8 to 38.9)
−5.8  
(−7.1 to −4.6)
42.1  
(41.3 to 42.9)
−5.8  
(−7.1 to −4.6)
46.4  
(45.6 to 47.1)
−5.8  
(−7.1 to −4.6)
52.4  
(51.3 to 53.4)
−5.8  
(−7.1 to −4.6)
0.0
Colon 71.0  
(70.1 to 72.0)
−7.9  
(−9.2 to −6.5)
73.5  
(72.9 to 74.1)
−7.4  
(−8.3 to −6.5)
76.0  
(75.3 to 76.7)
−7.0  
(−7.7 to −6.2)
81.6  
(80.6 to 82.5)
−6.3  
(−7.7 to −5.0)
1.6
Rectum 77.9  
(77.0 to 78.8)
−9.4  
(−10.7 to −8.0)
80.0  
(79.5 to 80.6)
−8.9  
(−9.8 to −8.0)
82.2  
(81.5 to 82.8)
−8.5  
(−9.2 to −7.7)
87.7  
(86.8 to 88.7)
−7.8  
(−9.2 to −6.5)
1.6
Liver 21.5  
(20.1 to 22.9)
−5.7  
(−7.4 to −3.9)
26.8  
(25.6 to 27.9)
−5.7  
(−7.4 to −3.9)
32.0  
(31.0 to 33.1)
−5.7  
(−7.4 to −3.9)
39.4  
(38.0 to 40.8)
−5.7  
(−7.4 to −3.9)
0.0
Pancreas 16.2  
(15.1 to 17.2)
−5.9  
(−7.1 to −4.7)
19.5  
(18.7 to 20.3)
−5.9  
(−7.1 to −4.7)
22.8  
(22.0 to 23.5)
−5.9  
(−7.1 to −4.7)
27.4  
(26.3 to 28.4)
−5.9  
(−7.1 to −4.7)
0.0
Larynx 85.9  
(84.7 to 87.1)
−6.3  
(−7.8 to −4.9)
86.5  
(85.6 to 87.5)
−6.3  
(−7.8 to −4.9)
87.2  
(86.4 to 88.1)
−6.3  
(−7.8 to −4.9)
88.2  
(87.0 to 89.4)
−6.3  
(−7.8 to −4.9)
0.0
Lung 25.9  
(25.2 to 26.7)
−4.0  
(−4.7 to −3.2)
28.6  
(28.1 to 29.1)
−4.0  
(−4.7 to −3.2)
31.3  
(30.6 to 32.0)
−4.0  
(−4.7 to −3.2)
38.6  
(37.7 to 39.4)
−4.0  
(−4.7 to −3.2)
0.0
Mesothelioma 29.7  
(27.6 to 31.9)
−2.9  
(−4.7 to −1.0)
30.9  
(29.3 to 32.5)
−2.9  
(−4.7 to −1.0)
37.1  
(36 to 38.3)
−2.9  
(−4.7 to −1.0)
45.9  
(44.2 to 47.6)
−2.9  
(−4.7 to −1.0)
0.0
Melanoma 94.8  
(93.9 to 95.6)
−6.2  
(−7.6 to −4.8)
95.6  
(95.0 to 96.1)
−5.2  
(−6.0 to −4.3)
96.4  
(95.9 to 96.9)
−4.1  
(−4.9 to −3.4)
97.5  
(96.6 to 98.3)
−2.7  
(−4.1 to −1.3)
3.5
Prostate 83.6  
(82.8 to 84.4)
−4.6  
(−5.7 to −3.6)
89.0  
(88.5 to 89.6)
−3.7  
(−4.3 to −3.0)
89.1  
(88.6 to 89.6)
−2.7  
(−3.3 to −2.1)
92.8  
(92.1 to 93.5)
−1.4  
(−2.4 to −0.3)
3.2
Testis 97.3  
(95.9 to 98.8)
−2.8  
(−4.5 to −1.1)
97.5  
(96.4 to 98.7)
−2.8  
(−4.5 to −1.1)
97.7  
(96.7 to 98.8)
−2.8  
(−4.5 to −1.1)
98.0  
(96.5 to 99.4)
−2.8  
(−4.5 to −1.1)
0.0
Bladder 85.6  
(84.6 to 86.6)
−5.8  
(−6.6 to −4.9)
81.7  
(80.9 to 82.5)
−5.8  
(−6.6 to −4.9)
80.9  
(80.1 to 81.7)
−5.8  
(−6.6 to −4.9)
83.0  
(82.1 to 83.9)
−5.8  
(−6.6 to −4.9)
0.0
Kidney 64.1  
(62.9 to 65.3)
−6.3  
(−7.6 to −5.1)
67.3  
(66.5 to 68.1)
−6.3  
(−7.6 to −5.1)
70.5  
(69.5 to 71.6)
−6.3  
(−7.6 to −5.1)
80.7  
(79.4 to 82.0)
−6.3  
(−7.6 to −5.1)
0.0
Brain 35.9  
(34.1 to 37.7)
−2.4  
(−4.9 to 0.1)
37.4  
(36.2 to 38.6)
−3.9  
(−5.5 to −2.3)
43.8  
(43.0 to 44.7)
−5.4  
(−6.7 to −4.0)
52.8  
(51.2 to 54.4)
−7.5  
(−10.0 to −5.0)
−5.1
Thyroid 84.4  
(82.1 to 86.7)
−2.7  
(−5.1 to −0.3)
84.6  
(83.1 to 86.2)
−2.7  
(−5.1 to −0.3)
84.9  
(82.8 to 86.9)
−2.7  
(−5.1 to −0.3)
92.3  
(89.8 to 94.8)
−2.7  
(−5.1 to −0.3)
0.0
Non-Hodgkin 
lymphoma
67.4  
(66.2 to 68.5)
−8.2  
(−9.9 to −6.4)
71.6  
(70.9 to 72.4)
−7.8  
(−8.9 to −6.7)
75.9  
(75.2 to 76.6)
−7.4  
(−8.4 to −6.5)
81.9  
(80.8 to 83.0)
−6.9  
(−8.6 to −5.1)
1.3
Hodgkin 
lymphoma
90.4  
(88.3 to 92.5)
−5.1  
(−8.3 to −2.0)
89.0  
(87.8 to 90.3)
−4.0  
(−6.1 to −2.0)
87.6  
(86.2 to 89.1)
−3.0  
(−4.7 to −1.2)
90.0  
(87.8 to 92.1)
−1.4  
(−4.6 to 1.7)
3.7
Myeloma 65.9  
(64.6 to 67.2)
−5.6  
(−7.0 to −4.3)
69.7  
(68.8 to 70.6)
−5.6  
(−7.0 to −4.3)
73.4  
(72.3 to 74.6)
−5.6  
(−7.0 to −4.3)
86.7  
(85.3 to 88.2)
−5.6  
(−7.0 to −4.3)
0.0
Leukaemia 65.1  
(64.0 to 66.2)
−5.3  
(−6.4 to −4.2)
66.6  
(65.9 to 67.4)
−5.3  
(−6.4 to −4.2)
68.2  
(67.2 to 69.1)
−5.3  
(−6.4 to −4.2)
75.2  
(74.0 to 76.4)
−5.3  
(−6.4 to −4.2)
0.0
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and the periods could vary substantially. The initial 
assumption was that changes would be expected 
after 2001 or 2006, or both but further analyses were 
conducted using more flexible models, which enabled 
the number and location of the knots to vary across all 
years of diagnosis. The estimates were not all identical, 
but they did not affect our main conclusions, in 
particular on the common absence of inflexion points 
in the trends in survival and in deprivation gap.
Short term net survival mostly reflects the speed of 
patient management (including diagnosis, staging, 
and first definitive treatment) as well as the quality 
of the surgical treatment and postoperative care. 
A persistent deficit in short term cancer survival in 
England (and more generally in the UK) compared 
with most wealthy countries has been observed for 
decades.34 35 Meanwhile, the wide socioeconomic 
inequalities in cancer survival, also seen for decades, 
are mostly due to higher short term mortality in more 
deprived patients.4
Although trends in cancer survival have been 
regularly used to inform governments on the progress 
towards the aims of their cancer policies,36 37 to our 
knowledge, little has been specifically published on 
the evaluation of how cancer policies impact survival 
and inequalities at national level. Most studies were 
at subnational level 38 or focused on very specific 
interventions, such as screening.39 By contrast, our 
study was designed to evaluate such policies. We 
acknowledge that changes in the survival trends 
are decided solely on acceleration in survival, and 
comparison with countries of similar wealth would 
put any observed improvements in perspective. This 
limitation, however, does not apply to our findings on 
the persistent socioeconomic inequalities in cancer 
survival. Furthermore, the weak evidence for an 
acceleration in cancer survival echoes the constant gap 
in cancer survival between England and some other 
wealthy countries.40 Our study also may be too early 
to detect the full impact of the recently implemented 
Table 3 | Adjusted one year survival and change in net survival for women with a diagnosis of one of 21 cancers between 1996 and 2013
Malignancy
1996 2001 2006 2013 1996-2013
Survival in 
most affluent 
(95% CI)
Deprivation 
gap (95% CI)
Survival in 
most affluent 
(95% CI)
Deprivation 
gap (95% CI)
Survival in 
most affluent 
(95% CI)
Deprivation gap 
(95% CI)
Survival in 
most affluent 
(95% CI)
Deprivation gap 
(95% CI)
Change in  
deprivation 
gap (%)
Oesophagus 35.7  
(34.2 to 37.2)
−8.0  
(−9.9 to −6.2)
40.6  
(39.4 to 41.8)
−8.0  
(−9.9 to −6.2)
45.5  
(44.4 to 46.6)
−8.0  
(−9.9 to −6.2)
52.3  
(50.8 to 53.8)
−8.0  
(−9.9 to −6.2)
0.0
Stomach 38.2  
(36.7 to 39.7)
−4.6  
(−6.4 to −2.8)
41.7  
(40.5 to 42.9)
−4.6  
(−6.4 to −2.8)
45.2  
(44.1 to 46.3)
−4.6  
(−6.4 to −2.8)
50.0  
(48.5 to 51.6)
−4.6  
(−6.4 to −2.8)
0.0
Colon 70.9  
(70.2 to 71.6)
−7.4  
(−8.3 to −6.5)
73.7  
(73.2 to 74.3)
−7.4  
(−8.3 to −6.5)
76.6  
(76.1 to 77.1)
−7.4  
(−8.3 to −6.5)
80.6  
(79.9 to 81.3)
−7.4  
(−8.3 to −6.5)
0.0
Rectum 75.8  
(74.4 to 77.2)
−5.9  
(−7.5 to −4.3)
80.0  
(79.0 to 81.0)
−6.1  
(−7.1 to −5.0)
80.5  
(79.7 to 81.4)
−6.3  
(−7.1 to −5.4)
86.8  
(85.7 to 87.9)
−6.5  
(−8.1 to −4.9)
−0.6
Liver 23.7  
(21.5 to 26.0)
−5.4  
(−8.1 to −2.6)
27.3  
(25.5 to 29.0)
−5.4  
(−8.1 to −2.6)
30.8  
(29.1 to 32.5)
−5.4  
(−8.1 to −2.6)
35.7  
(33.4 to 38.0)
−5.4  
(−8.1 to −2.6)
0.0
Pancreas 16.3  
(15.4 to 17.2)
−5.8  
(−6.9 to −4.8)
20.6  
(19.9 to 21.3)
−5.8  
(−6.9 to −4.8)
24.9  
(24.2 to 25.5)
−5.8  
(−6.9 to −4.8)
30.9  
(30.0 to 31.8)
−5.8  
(−6.9 to −4.8)
0.0
Lung 27.2  
(26.1 to 28.3)
−3.7  
(−5.1 to −2.4)
32.5  
(31.7 to 33.3)
−4.0  
(−4.9 to −3.2)
35.0  
(34.3 to 35.7)
−4.3  
(−5.1 to −3.6)
45.8  
(44.9 to 46.7)
−4.8  
(−6.1 to −3.5)
−1.1
Mesothelioma 32.6  
(29.9 to 35.2)
−8.3  
(−11.5 to −5.1)
37.9  
(35.8 to 39.9)
−8.3  
(−11.5 to −5.1)
43.2  
(41.2 to 45.1)
−8.3  
(−11.5 to −5.1)
50.6  
(47.9 to 53.2)
−8.3  
(−11.5 to −5.1)
0.0
Melanoma 96.9  
(96.5 to 97.3)
−1.9  
(−2.3 to −1.6)
97.3  
(97.0 to 97.5)
−1.9  
(−2.3 to −1.6)
97.7  
(97.4 to 98.0)
−1.9  
(−2.3 to −1.6)
99.6  
(99.2 to 100)
−1.9  
(−2.3 to −1.6)
0.0
Breast 91.1  
(90.7 to 91.5)
−3.2  
(−3.6 to −2.8)
93.9  
(93.6 to 94.2)
−3.2  
(−3.6 to −2.8)
95.5  
(95.2 to 95.7)
−3.2  
(−3.6 to −2.8)
97.7  
(97.4 to 98.1)
−3.2  
(−3.6 to −2.8)
0.0
Cervix 84.9  
(83.0 to 86.8)
−7.0  
(−9.3 to −4.7)
82.8  
(81.5 to 84.0)
−6.0  
(−7.4 to −4.5)
83.4  
(82.5 to 84.3)
−4.9  
(−6.2 to −3.7)
84.3  
(82.9 to 85.7)
−3.5  
(−5.7 to −1.2)
3.5
Uterus 86.2  
(85.3 to 87.1)
−5.8  
(−7.2 to −4.4)
87.7  
(87.1 to 88.2)
−5.0  
(−5.9 to −4.1)
89.1  
(88.6 to 89.6)
−4.2  
(−4.9 to −3.4)
91.2  
(90.3 to 92.0)
−3.0  
(−4.4 to −1.6)
2.8
Ovary 62.5  
(61.6 to 63.4)
−6.8  
(−7.7 to −5.8)
65.8  
(65.2 to 66.4)
−6.8  
(−7.7 to −5.8)
69.1  
(68.3 to 70.0)
−6.8  
(−7.7 to −5.8)
76.9  
(75.9 to 77.9)
−6.8  
(−7.7 to −5.8)
0.0
Bladder 79.4  
(77.6 to 81.2)
−8.6  
(−10.2 to −7.1)
72.5  
(71.1 to 73.8)
−8.6  
(−10.2 to −7.1)
72.1  
(71.1 to 73.1)
−8.6  
(−10.2 to −7.1)
71.6  
(70.1 to 73)
−8.6  
(−10.2 to −7.1)
0.0
Kidney 61.7  
(60.2 to 63.1)
−4.7  
(−6.2 to −3.1)
65.6  
(64.6 to 66.6)
−4.7  
(−6.2 to −3.1)
69.5  
(68.2 to 70.8)
−4.7  
(−6.2 to −3.1)
80.3  
(78.7 to 81.9)
−4.7  
(−6.2 to −3.1)
0.0
Brain 35.8  
(34.4 to 37.1)
−4.2  
(−5.9 to −2.6)
40.2  
(39.1 to 41.2)
−4.2  
(−5.9 to −2.6)
44.6  
(43.6 to 45.6)
−4.2  
(−5.9 to −2.6)
50.8  
(49.4 to 52.1)
−4.2  
(−5.9 to −2.6)
0.0
Thyroid 84.4  
(82.9 to 85.9)
−2.6  
(−4.4 to −0.9)
87.7  
(86.5 to 88.8)
−2.6  
(−4.4 to −0.9)
90.9  
(89.9 to 92)
−2.6  
(−4.4 to −0.9)
95.5  
(94.1 to 97.0)
−2.6  
(−4.4 to −0.9)
0.0
Non-Hodgkin 
lymphoma
70.4  
(69.7 to 71.2)
−7.1  
(−8.0 to −6.2)
74.8  
(74.2 to 75.4)
−7.1  
(−8.0 to −6.2)
79.2  
(78.6 to 79.7)
−7.1  
(−8.0 to −6.2)
85.3  
(84.6 to 86.1)
−7.1  
(−8.0 to −6.2)
0.0
Hodgkin 
lymphoma
88.9  
(86.9 to 90.8)
−1.9  
(−3.6 to −0.2)
91.1  
(89.4 to 92.8)
−1.9  
(−3.6 to −0.2)
88.9  
(87.3 to 90.5)
−1.9  
(−3.6 to −0.2)
93.0  
(91.3 to 94.8)
−1.9  
(−3.6 to −0.2)
0.0
Myeloma 63.9  
(62.6 to 65.2)
−3.4  
(−4.9 to −1.8)
69.4  
(68.4 to 70.4)
−3.4  
(−4.9 to −1.8)
74.9  
(73.9 to 75.9)
−3.4  
(−4.9 to −1.8)
82.6  
(81.3 to 83.9)
−3.4  
(−4.9 to −1.8)
0.0
Leukaemia 62.4  
(61.2 to 63.6)
−6.5  
(−7.9 to −5.0)
65.3  
(64.3 to 66.2)
−6.5  
(−7.9 to −5.0)
68.1  
(67.2 to 69.0)
−6.5  
(−7.9 to −5.0)
72.1  
(70.9 to 73.3)
−6.5  
(−7.9 to −5.0)
0.0
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cancer initiatives, although it confirms the findings 
of our earlier studies.11 33 Such studies should be 
regularly updated.
Meaning of the study
Since the introduction of the NHS Cancer Plan 
(2000), acceleration in the positive survival trends 
was witnessed only for a few cancers and mostly 
among men, who experienced a lower initial increase 
compared with women (cancer of the lung, brain, and 
thyroid, mesothelioma, myeloma, and leukaemia). 
No such acceleration was found among women. For 
lung cancer, and more specifically non-small cell 
carcinoma, the proportion of patients receiving a 
surgical treatment was low in England,41 but this 
proportion increased from around 10% until 200842 to 
17% in 2015.43 This improvement may be partly the 
result of a higher number of specialised surgeons44 
and a higher proportion of patients managed in 
specialised centres, which could reduce the variability 
in postoperative mortality.45 These changes may have 
impacted the outcome for mesothelioma, too. The 
continuous expansion in the availability of diagnostic 
tools (eg, computed tomography, magnetic resonance 
imaging, ultrasound machines) in England is likely 
to have increased the proportion of brain and thyroid 
tumours diagnosed at an earlier stage.46 Survival 
pattern for bladder cancer is particular as one year 
survival decreased slightly between 1996 and 2001, 
then stabilised. It reflects a change in coding around 
2000, under which papillomas were reclassified from 
invasive to uncertain (whether benign or malignant), 
therefore excluded from survival analyses. Omitting 
these tumours with a good prognosis resulted 
in a decrease in cancer survival.47 Despite these 
improvements in survival there was no reduction in 
the inequalities in survival from lung, brain, or thyroid 
tumour, or from mesothelioma.
Particular efforts were dedicated in England to 
high incidence cancers with intermediate prognosis 
(one year survival between 40% and 65% in 1996) 
such as colon and rectal cancers, and one could 
have expected a faster improvement in survival and 
a reduction of the deprivation gap after the policy 
initiatives. Survival from these cancers in England 
remained behind internationally,40 48 and inequalities 
in survival from these cancers hardly narrowed. Short 
term survival increased dramatically since 1996 for 
most other digestive cancers with poor prognosis (one 
year survival <40% in 1996), but the more deprived 
patients still experienced lower survival.
It is likely that the longstanding deficit in survival 
and the socioeconomic inequalities in survival in 
England share the same causal factors, which can be 
grouped into patient, tumour, and healthcare system 
factors. The National Awareness and Early Diagnosis 
Initiative49 and the Be Clear on Cancer Campaign50 
aimed specifically to tackle some of the patient related 
(cancer awareness, barriers) and tumour related 
(tumour stage) issues. Although cancer awareness 
varies internationally51 and by deprivation,52 it seems 
to explain none of the international disparities in cancer 
survival51 and little of socioeconomic inequalities.53 A 
lot of effort has also gone into diagnosing cancers at 
an earlier stage. Patients tend to have a diagnosis of 
more advanced tumours in England compared with 
wealthy countries,54-57 and among the more deprived 
patients compared with the least deprived.9 However, 
as stage specific survival tends to be lower in England, 
more advanced stage would explain only part of the 
international54-57 and socioeconomic inequalities in 
cancer survival.58 59 A higher proportion of patients 
are now receiving a diagnosis through Two Week Wait 
or GP referral while for some cancers there is a major 
decrease in emergency presentation.60 Although stage 
distribution might have slightly moved towards earlier 
stages, the picture remains patchy and there was 
no evidence to suggest a narrowing of these gaps in 
survival.
These policy initiatives put a greater emphasis on 
individual factors than on the observed suboptimal 
management of patients with cancer. The variations 
in cancer management (eg, differential route to 
diagnosis, staging investigation, treatment) are 
likely to explain some of the low survival observed in 
England and among more deprived patients, whereas 
the role of the individual factors in the observed 
variations in management seems minor. For example, 
the background consultation rate in primary care of 
patients with cancer does not differ between routes to 
cancer diagnosis (emergency presentation or not).61 62 
In contrast, interventions on healthcare system factors 
might have a large impact on cancer survival, as shown 
by the recent changes in the management of patients 
with lung cancer.43 However, such interventions 
have not influenced the socioeconomic inequalities 
in cancer survival yet, possibly because they do not 
directly address the differential interactions between 
the healthcare system and the patients, which could 
lead to suboptimal management of subgroups of the 
population.
Conclusion and policy implications
Little evidence has been found about the acceleration 
in cancer survival after the successive national cancer 
policy initiatives. Survival in the most deprived has 
been consistently lower and the deprivation gap has 
shown little change over the years for patients with a 
diagnosis during 1971-902 and 1986-9963 in England 
and Wales. This study contributes with more recent 
data and updates evidence that the deprivation gap 
persisted in England even after the introduction of 
successive national policies, which among other goals 
targeted social inequalities related to cancer.11
These findings should be taken into consideration 
by cancer policy makers and inform future initiatives. 
Shifting the focus from individual factors to 
healthcare system factors might prove to be beneficial 
in improving cancer outcomes among the most 
disadvantaged. Further research on these factors can 
help shed light and improve the efficacy of future 
cancer policies.
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